Clinical Trials Browser

Terminated × OTHER × talimogene laherparepvec × Clear all

NCT04185311 2023-08-15

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Phase 1 Terminated

Breast Carcinoma In Situ, Triple Negative Breast Neoplasms

NCT02658812 2023-01-25

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

11 enrolled 16 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03597009 2021-04-20

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

Phase 1/2 Terminated

1 enrolled 12 charts

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant